{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:48:43Z","timestamp":1790858923325,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770202"],"award-info":[{"award-number":["81770202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470304"],"award-info":[{"award-number":["81470304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province","award":["JBZX-201904"],"award-info":[{"award-number":["JBZX-201904"]}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H080002"],"award-info":[{"award-number":["LY21H080002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12185-020-03070-x","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T03:03:18Z","timestamp":1609729398000},"page":"751-759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-9411","authenticated-orcid":false,"given":"Chan","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Xia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di-Ying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"3070_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.leukres.2018.08.014","volume":"73","author":"GS Guru Murthy","year":"2018","unstructured":"Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018;73:21\u20133.","journal-title":"Leuk Res"},{"issue":"20","key":"3070_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"9","key":"3070_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.clml.2019.06.002","volume":"19","author":"S Venugopal","year":"2019","unstructured":"Venugopal S, Zhou S, El Jamal SM, Lane AA, Mascarenhas J. Blastic plasmacytoid dendritic cell neoplasm-current insights. Clin Lymphoma Myeloma Leuk. 2019;19(9):545\u201354.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"3070_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/modpathol.2015.145","volume":"29","author":"F Facchetti","year":"2016","unstructured":"Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98\u2013111.","journal-title":"Mod Pathol"},{"issue":"2","key":"3070_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/bjh.14146","volume":"174","author":"L Pagano","year":"2016","unstructured":"Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188\u2013202.","journal-title":"Br J Haematol"},{"issue":"11","key":"3070_CR6","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1182\/blood.V99.11.4154","volume":"99","author":"D Leroux","year":"2002","unstructured":"Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood. 2002;99(11):4154\u20139.","journal-title":"Blood"},{"issue":"11","key":"3070_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","volume":"18","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Reljic T, Murthy HS, Ayala E, Kumar A. Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18(11):703-709.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"3070_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/MPH.0000000000000964","volume":"39","author":"MJ Kim","year":"2017","unstructured":"Kim MJ, Nasr A, Kabir B, de Nanassy J, Tang K, Menzies-Toman D, et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review. J Pediatr Hematol Oncol. 2017;39(7):528\u201337.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"3070_CR9","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","volume":"95","author":"AG Jegalian","year":"2010","unstructured":"Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873\u20139.","journal-title":"Haematologica"},{"issue":"9","key":"3070_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/13543784.2018.1512970","volume":"27","author":"D Kerr","year":"2018","unstructured":"Kerr D, Sokol L. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. Expert Opin Investig Drugs. 2018;27(9):733\u20139.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9583","key":"3070_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240\u201350.","journal-title":"Lancet"},{"key":"3070_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.critrevonc.2016.09.003","volume":"107","author":"U Falcone","year":"2016","unstructured":"Falcone U, Sibai H, Deotare U. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol. 2016;107:156\u201362.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3070_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11864-019-0605-x","volume":"20","author":"D Kerr","year":"2019","unstructured":"Kerr D, Zhang L, Sokol L. Blastic plasmacytoid dendritic cell neoplasm. Curr Treat Options Oncol. 2019;20(1):9.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"3070_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.bbmt.2016.03.022","volume":"22","author":"K Laribi","year":"2016","unstructured":"Laribi K, Denizon N, Besan\u00e7on A, Farhi J, Lemaire P, Sandrini J, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357\u201367.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3070_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian Multicenter Study. Haematologica. 2013;98(2):239\u201346.","journal-title":"Haematologica"},{"issue":"1","key":"3070_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2133.2009.09373.x","volume":"162","author":"S Dalle","year":"2010","unstructured":"Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice. Br J Dermatol. 2010;162(1):74\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3070_CR17","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","volume":"99","author":"J Feuillard","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F, Maynadi\u00e9 M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556\u201363.","journal-title":"Blood"},{"issue":"22","key":"3070_CR18","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.18632\/oncotarget.4146","volume":"6","author":"L Mart\u00edn-Mart\u00edn","year":"2015","unstructured":"Mart\u00edn-Mart\u00edn L, L\u00f3pez A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015;6(22):19204\u201316.","journal-title":"Oncotarget"},{"issue":"7","key":"3070_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","volume":"32","author":"P Reimer","year":"2003","unstructured":"Reimer P, R\u00fcdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated. Bone Marrow Transplant. 2003;32(7):637\u201346.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3070_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MPH.0000000000000812","volume":"39","author":"A Tom\u00e9","year":"2017","unstructured":"Tom\u00e9 A, Pragosa H, Caldas G, Lacerda A, Pereira F. Pediatric blastic plasmacytoid dendritic cell neoplasm: how to treat. J Pediatr Hematol Oncol. 2017;39(4):323.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"15","key":"3070_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMc1808354","volume":"379","author":"ME Agha","year":"2018","unstructured":"Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2018;379(15):1479\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"3070_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156\u201364.","journal-title":"Cancer Discov"},{"issue":"23","key":"3070_CR23","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"T Aoki","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559\u201362.","journal-title":"Blood"},{"issue":"5","key":"3070_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017;179(5):781\u20139.","journal-title":"Br J Haematol"},{"issue":"7","key":"3070_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","volume":"19","author":"MA Kharfan-Dabaja","year":"2013","unstructured":"Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"3070_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440\u20136.","journal-title":"Blood"},{"issue":"17","key":"3070_CR27","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628\u201337.","journal-title":"N Engl J Med"},{"issue":"1","key":"3070_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-018-0604-6","volume":"11","author":"W Sun","year":"2018","unstructured":"Sun W, Liu H, Kim Y, Karras N, Pawlowska A, Toomey D, et al. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. J Hematol Oncol. 2018;11(1):61.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3070_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2013.283","volume":"28","author":"J Menezes","year":"2014","unstructured":"Menezes J, Acquadro F, Wiseman M, G\u00f3mez-L\u00f3pez G, Salgado RN, Talavera-Casa\u00f1as JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823\u20139.","journal-title":"Leukemia"},{"issue":"7","key":"3070_CR30","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/leu.2017.101","volume":"31","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Suzuki Y, Hama A, Muramatsu H, Nakatochi M, Gunji M, et al. Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2017;31(7):1629\u201333.","journal-title":"Leukemia"},{"key":"3070_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2019.05.024","volume":"458","author":"RJ Fagan","year":"2019","unstructured":"Fagan RJ, Dingwall AK. COMPASS ascending: emerging clues regarding the roles of MLL3\/KMT2C and MLL2\/KMT2D proteins in cancer. Cancer Lett. 2019;458:56\u201365.","journal-title":"Cancer Lett"},{"key":"3070_CR32","doi-asserted-by":"publisher","first-page":"108997","DOI":"10.1016\/j.biopha.2019.108997","volume":"116","author":"X Chen","year":"2019","unstructured":"Chen X, Zhang G, Chen B, Wang Y, Guo L, Cao L, et al. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. Biomed Pharmacother. 2019;116:108997.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3070_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13148-019-0802-2","volume":"12","author":"WJ Lavery","year":"2020","unstructured":"Lavery WJ, Barski A, Wiley S, Schorry EK, Lindsley AW. KMT2C\/D COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital regulopathies. Clin Epigenet. 2020;12(1):10.","journal-title":"Clin Epigenet"},{"issue":"5","key":"3070_CR34","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ccr.2014.03.016","volume":"25","author":"C Chen","year":"2014","unstructured":"Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell. 2014;25(5):652\u201365.","journal-title":"Cancer Cell"},{"issue":"3","key":"3070_CR35","doi-asserted-by":"publisher","first-page":"e46821","DOI":"10.15252\/embr.201846821","volume":"20","author":"T Rampias","year":"2019","unstructured":"Rampias T, Karagiannis D, Avgeris M, Polyzos A, Kokkalis A, Kanaki Z, et al. The lysine-specific methyltransferase KMT2C\/MLL3 regulates DNA repair components in cancer. EMBO Rep. 2019;20(3):e46821.","journal-title":"EMBO Rep"},{"issue":"34","key":"3070_CR36","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41388-018-0273-5","volume":"37","author":"K Gala","year":"2018","unstructured":"Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, et al. KMT2C mediates the estrogen dependence of breast cancer through regulation of ER\u03b1 enhancer function. Oncogene. 2018;37(34):4692\u2013710.","journal-title":"Oncogene"},{"issue":"6","key":"3070_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/ejh.12972","volume":"99","author":"S Kayser","year":"2017","unstructured":"Kayser S, Feszler M, Krzykalla J, Schick M, Kramer M, Benner A, et al. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. Eur J Haematol. 2017;99(6):544\u201352.","journal-title":"Eur J Haematol"},{"issue":"22","key":"3070_CR38","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/blood-2015-05-646240","volume":"126","author":"M Garg","year":"2015","unstructured":"Garg M, Nagata Y, Kanojia D, Mayakonda A, Yoshida K, Haridas Keloth S, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015;126(22):2491\u2013501.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03070-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T13:25:22Z","timestamp":1620480322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03070-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3070"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03070-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}